AIM Rule 26

Arecor Therapeutics plc is focused on transforming patient care by enhancing existing therapeutic medicines to bring safer, more effective and convenient treatments to patients.

Arecor Therapeutics plc, headquartered in the United Kingdom, is registered in England and Wales, company number 13331147. The registered office is at Chesterford Research Park, Little Chesterford, Saffron Walden, CB10 1XL, U.K.

• Dr Andrew Richards, Non-Executive Chairman
• Dr Sarah Howell, Chief Executive Officer
• Dr Sam Fazeli, Independent Non-Executive Director
• Jeremy Morgan, Independent Non-Executive Director
• Dr Alan Smith, Non-Executive Director
• Christine Soden, Independent Non-Executive Director

The Board meets regularly and at least 8 times per year. The Board has adopted terms of reference including a schedule of matters reserved for the Board with a clear focus on strategy and management, structure and capital, business policies, financial reporting and controls.

The Directors support high standards of corporate governance and apply the principles of the Quoted Company Alliance Corporate Governance Code the (‘QCA Code’), as part of the Group’s governance framework.

Articles of Association and Admission Document

The Company’s ordinary shares are listed on AIM, a market operated by the London Stock Exchange, under the symbol “AREC”.  The Company is not listed on any other exchanges or trading platforms.

There are no restrictions on the transfer of shares.

Click here to view the Company’s RNS Announcements.

Details of nominated adviser and other key advisers.

Arecor Therapeutics plc is subject to the UK City Code on Takeovers and Mergers.